Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies

David S. Siegel, MD PhD, Andrew McDonald, MBChB, Nicolas Novitzky, MD PhD, William Bensinger, Michael Craig, MD, Frits van Rhee, MD PhD, Martin Gutierrez, MD, Edward N. Libby, MD, John Thompson, Alice S Bexon, MD, Charles Barranco, Catherine A Taylor, Richard Dondero, Leslie J. Browne, PhD, Michael R. Kurman, MD, John A. Lust, MD PhD

Blood (2014) 124 (21): 4464.

https://doi.org/10.1182/blood.V124.21.4464.4464

Published: 2014

Journal Articles

Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study

Alice S Bexon, MD, Michael Craig, MD, David S. Siegel, MD PhD, William Bensinger, Nicolas Novitzky, MD PhD, Andrew McDonald, MBChB, Martin Gutierrez, MD, Edward N. Libby, MD, Frits van Rhee, MD PhD, Jeremy Heidel, PhD, John Thompson, Charles Barranco, Catherine A Taylor, Kathleen A. Donovan, PhD, Laurie L. Moon-Tasson, BA, Leslie J. Browne, PhD, Michael R. Kurman, MD, John A. Lust, MD PhD, Richard Dondero

Blood (2014) 124 (21): 2121.

https://doi.org/10.1182/blood.V124.21.2121.2121

Published: 2014

Journal Articles

Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study To Evaluate The Safety and Tolerability Of Intravenous Infusion Of SNS01-T In Patients With Relapsed Or Refractory Multiple Myeloma, Mantle Cell Lymphoma, Or Diffuse Large B Cell Lymphoma

John A Lust, Charles Barranco, Saad Z Usmani, MD FACP, Frits van Rhee, MD, PhD, Mehdi Hamadani, MD, John Thompson, Catherine A Taylor, Richard Dondero, Leslie J. Browne, PhD, David Siegel, William I. Bensinger, MD

Blood (2013) 122 (21): 1950.

https://doi.org/10.1182/blood.V122.21.1950.1950

Published: 2013

Journal Articles

SNS01-T Exhibits Significant Anti-Tumoral Activity In Models Of Multiple Myeloma and Non-Hodgkins B Cell Lymphoma and Induces Cell Death In Malignant But Not Normal B Cells

Catherine A Taylor, Terence Tang, Sarah Francis, Zhongda Liu, Qifa Zheng, Richard Dondero, John Thompson

Blood (2013) 122 (21): 880.

https://doi.org/10.1182/blood.V122.21.880.880

Published: 2013

Journal Articles

Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.

John A Lust, MD, PhD, Saad Z Usmani, MD FACP, Mehdi Hamadani, MD, Charles Barranco, Martha Q Lacy, MD, Angela Dispenzieri, MD, Morie A Gertz, David Dingli, M.D., Ph.D., Stephen Russell, MD, PhD, Francis K Buadi, M.D., Steven R Zeldenrust, MD, PhD, Suzanne R Hayman, MD, S. Vincent Rajkumar, MD, Shaji K. Kumar, MD, John Thompson, Catherine A Taylor, Richard Dondero

Blood (2012) 120 (21): 2973.

https://doi.org/10.1182/blood.V120.21.2973.2973

Published: 2012

Journal Articles

Combination Therapy with Novel Nanoparticle, SNS01-T, and Lenalidomide Triggers Synergistic Cytotoxicity in Vitro and in Vivo in Multiple Myeloma and Mantle Cell Lymphoma

Catherine A Taylor, Terence Tang, Zhongda Liu, Sarah Francis, Zheng Qifa, Richard Dondero, John Thompson

Blood (2012) 120 (21): 4223.

https://doi.org/10.1182/blood.V120.21.4223.4223

Published: 2012

Journal Articles

Pharmacodynamic, Biodistribution and Toxicology Results for SNS01-T, a Nanoparticle That Targets eIF5A for the Treatment of Multiple Myeloma

Richard Dondero, Saad Usmani, MD, FACP, Catherine A Taylor, Zhongda Liu, Tang Terence, John Thompson

Blood (2011) 118 (21): 2051.

https://doi.org/10.1182/blood.V118.21.2051.2051

Published: 2011

NARROW

Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies

Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study

Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study To Evaluate The Safety and Tolerability Of Intravenous Infusion Of SNS01-T In Patients With Relapsed Or Refractory Multiple Myeloma, Mantle Cell Lymphoma, Or Diffuse Large B Cell Lymphoma

SNS01-T Exhibits Significant Anti-Tumoral Activity In Models Of Multiple Myeloma and Non-Hodgkins B Cell Lymphoma and Induces Cell Death In Malignant But Not Normal B Cells

Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.

Combination Therapy with Novel Nanoparticle, SNS01-T, and Lenalidomide Triggers Synergistic Cytotoxicity in Vitro and in Vivo in Multiple Myeloma and Mantle Cell Lymphoma

Pharmacodynamic, Biodistribution and Toxicology Results for SNS01-T, a Nanoparticle That Targets eIF5A for the Treatment of Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies

Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study

Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study To Evaluate The Safety and Tolerability Of Intravenous Infusion Of SNS01-T In Patients With Relapsed Or Refractory Multiple Myeloma, Mantle Cell Lymphoma, Or Diffuse Large B Cell Lymphoma

SNS01-T Exhibits Significant Anti-Tumoral Activity In Models Of Multiple Myeloma and Non-Hodgkins B Cell Lymphoma and Induces Cell Death In Malignant But Not Normal B Cells

Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.

Combination Therapy with Novel Nanoparticle, SNS01-T, and Lenalidomide Triggers Synergistic Cytotoxicity in Vitro and in Vivo in Multiple Myeloma and Mantle Cell Lymphoma

Pharmacodynamic, Biodistribution and Toxicology Results for SNS01-T, a Nanoparticle That Targets eIF5A for the Treatment of Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only